계명대학교 의학도서관 Repository

Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma

Metadata Downloads
Author(s)
도영록
Alternative Author(s)
Do, Young Rok
Issued Date
2008
Abstract
Background: Bortezomib has significantly advanced the treatment of patients with multiple myeloma (MM). However, considering that most patients
with MM are elderly, bortezomib-related morbidity should be thoroughly studied to ensure the safe use of this drug. Herpes zoster has been reported
as a possible adverse event associated with bortezomib because a major target of bortezomib, nuclear factor–κB, is known to be involved with
T-cell immunity. Patients and Methods: We performed a retrospective analysis of the incidence of herpes zoster among 282 patients treated with a
bortezomib-containing regimen. Results: During the patients’ pre-bortezomib treatment (median, 2.14 years), the incidence of herpes zoster was 11%
(31 of 282 patients). However, after the patients were treated with bortezomib, the incidence increased to 22.3% (63 of 282 patients), of which almost
all occurrences were within the first 3 cycles (median duration, 41 days). The time interval from diagnosis to bortezomib initiation date was shorter in
herpes zoster–positive patients than in herpes zoster–negative patients (2.14 ± 1.87 years vs. 3.38 ± 2.95 years; P = .002). Disease duration, previous
herpes zoster infection, disease stage and type of myeloma, and the type and intensity of previous treatments failed to show any relationship with
herpes zoster. These findings suggest that longer history of disease and treatments did not affect the occurrence of herpes zoster, nor did the type of
bortezomib regimens or their toxicities. Conclusion: Bortezomib can increase the incidence of herpes zoster regardless of disease duration, previous
treatments, and concomitantly administered drugs. Thus, the occurrence of herpes zoster should be monitored during bortezomib treatment.
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Clinical Lymphoma, Myeloma and Leukemia, Vol.8(4) : 237-240, 2008
Type
Article
ISSN
1557-9190
DOI
10.3816/CLM.2008.n.031
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35496
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.